STAR

Hypoxic-ischemic encephalopathy (HIE) affects approximately 4,000 to 12,000 persons annually in the United States. Mortality from HIE has been reported up to 60%, with at least 25% of survivors left with significant neurocognitive disability. Despite this vital unmet medical need, no pharmacological adjunct or alternative therapy has proven beneficial in improving outcomes in neonatal HIE.

RLS-0071 is a novel peptide being developed for the treatment of neonatal HIE. This study is designed to evaluate the safety and tolerability of RLS-0071 in the treatment of newborns with moderate or severe HIE.

This is a Phase 2, two-stage, multisite, randomized, double-blind, placebo-controlled, multiple-ascending dose study of RLS-0071 to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy in newborns with moderate or severe HIE undergoing therapeutic hypothermia.

In Stage 1, participants will receive either ascending doses of RLS-0071 or a matched volume of placebo for 72 hours in addition to standard of care treatment, including therapeutic hypothermia. During and after the dosing period, participants will be monitored and assessed for safety and exploratory evaluations through Day 14. After completion of Stage 1, participants will transition to Stage 2 of the study for long-term observation until participants reach 24 months of age.

The first cohort subsets, consisting of Cohort 1a (moderate HIE) and 1b (severe HIE), will receive a dose of 3 mg/kg RLS-0071 or a matched volume of placebo every 8 hours (q8h). A Data Safety Monitoring Board (DSMB) will review available clinical safety and PK data from Cohort 1 subsets with completed study intervention, and make a recommendation on whether to escalate the dose for moderate and severe HIE cohorts. The Sponsor will consider the DSMB recommendation to make their decision on dose escalation in addition to their own evaluation of all available safety and PK data. If the decision is made to escalate, Cohort 2 subsets (2a [moderate] and 2b [severe]) will be recruited to receive an escalated dose of RLS-0071 (10 mg/kg) or a matched volume of placebo. Upon DSMB data review of data from Cohort 2 subsets and Sponsor approval of further dose escalation, Cohort 3 subsets (3a [moderate] and 3b [severe]) will be recruited to receive 20 mg/kg RLS-0071 or a matched volume of placebo.

Inclusion Criteria:

1. ≥ 36 weeks gestation.

2. Sentinel event prior to delivery such as abruption, tight nuchal cord, uterine rupture, profound bradycardia, shoulder dystocia, or cord prolapse or other acute event likely attributable for newborn depression at delivery or an acute change in the fetal status with a clinical presentation consistent with an acute sentinel event with no clearly defined etiology.

3. Moderate or severe encephalopathy based on at least one risk of encephalopathy criterion (a) and one clinical signs of encephalopathy criterion (b):

   1. Risk of encephalopathy (either):

      • Blood gas drawn within 1 hour of birth, either arterial blood gas (ABG) (cord or infant) or venous blood gas (VBG) (infant) with pH ≤ 7.0 OR base deficit ≥ 16 mmol/L. OR

      • Blood gas drawn within 1 hour of birth, either ABG (cord or infant) or VBG (infant) with pH 7.01 to 7.15, a base deficit between 10 and 15.9 mmol/L, or a blood gas was not available, additional criteria are required:

        • Infant born after an acute perinatal event (eg, late or variable decelerations, cord prolapse, cord rupture, uterine rupture, maternal trauma, hemorrhage or cardiorespiratory arrest) and the APGAR score ≤ 5 at 10 minutes OR

        • The infant required assisted ventilation ≥ 10 minutes after birth (ie, endotracheal or mask ventilation).

   2. Clinical signs of encephalopathy (either/both):

      • Moderate/Severe encephalopathy on National Institute of Child Health and Human Development assessment.

      • Evidence of seizures (clinical and/or electroencephalogram).

4. Be eligible to receive therapeutic hypothermia.

5. Active whole-body cooling to be started prior to 6 hours of age (passive cooling is permitted prior to active whole body cooling).

6. Product of a singleton pregnancy.

7. Written informed consent obtained from parent or legal guardian.

Exclusion Criteria:

1. Inability to enroll in the study and initiate the first dose of RLS-0071 within 10 hours of life.

2. Known major congenital and/or chromosomal abnormality(ies).

3. Severe growth restriction (birth weight ≤ 1800 g).

4. Prenatal diagnosis of brain abnormality or hydrocephalus.

5. Patient's head circumference is < 30 cm.

6. 10-minute appearance, pulse, grimace, activity, and respiration (APGAR) score < 2

7. Infants suspected of overwhelming sepsis or congenital infection based on the Investigator's clinical consideration at the time of enrollment.

8. Persistent severe hypotension unresponsive to inotropic support (requiring >2 inotropes, not inclusive of hydrocortisone).

9. Persistent severe hypoxia in the setting of 100% fraction of inspired oxygen (FiO₂) and unresponsive to nitric oxide or requiring extracorporeal membrane oxygenation (ECMO).

10. Severe disseminated intravascular coagulation with clinical bleeding.

11. Neonatal encephalopathy believed to be due to a cause other than perinatal hypoxia

(ie, other than HIE).

1. Moribund infants for whom withdrawal of care being considered.

2. Suspected or confirmed fetal alcohol syndrome or suspected substance withdraw

seizures.

1. Any other condition that the investigator may consider would make the patient

ineligible for the study or place the patient at an unacceptable risk (Note: this

criterion would include a clinically significant [eg, Grade 3 or 4] intracranial

hemorrhage).